Prepare for a new Pharma Cycle: Verona Pharma
VRNA is developing novel treatments to enhance the lives of those affected by chronic lung conditions. Recently their medication against the common disease called COPD got approved. 600 million people worldwide suffer from this disease, the market is huge. The Company is led by an experienced management team with an established track record in the discovery, clinical development and commercialization of respiratory therapeutics. The revenue of this medication is expected to grow from 9 million dollars 2024 to 740 million dollars 2027. The chart looks good as well, the price broke over a midterm resistance and turned it into support. Beforehand a Double-Bottom formed, indicating a Target of around 30 dollars. If a new Pharma- and Biotech-Cycle starts, Verona could rise to 75 dollars by the beginning of 2025. 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.